ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

ClinicalTrials.gov ID: NCT00080314

Public ClinicalTrials.gov record NCT00080314. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode

Study identification

NCT ID
NCT00080314
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Enrollment
400 participants

Conditions and interventions

Interventions

  • Aripiprazole Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2003
Primary completion
Sep 30, 2006
Completion
Sep 30, 2006
Last update posted
Nov 10, 2013

2004 – 2006

United States locations

U.S. sites
28
U.S. states
18
U.S. cities
28
Facility City State ZIP Site status
Local Institution Tuscaloosa Alabama
Local Institution Little Rock Arkansas
Local Institution San Diego California
Local Institution Sherman Oaks California
Local Institution Norwich Connecticut
Local Institution West Haven Connecticut
Local Institution Jacksonville Florida
Local Institution Maitland Florida
Local Institution Orlando Florida
Local Insstitution Honolulu Hawaii
Local Institution Chicago Illinois
Local Institution Lake Charles Louisiana
Local Institution Rockville Maryland
Local Institution Durham North Carolina
Local Institution Raleigh North Carolina
Local Institution Beachwood Ohio
Local Institution Dayton Ohio
Local Institution Oklahoma City Oklahoma
Local Institution Portland Oregon
Local Institution Media Pennsylvania
Local Institution Memphis Tennessee
Local Institution Austin Texas
Local Institution Dallas Texas
Local Institution Houston Texas
Local Institution Lake Jackson Texas
Local Institution Wichita Falls Texas
Local Institution Arlington Virginia
Local Institution Bellevue Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00080314, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 10, 2013 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00080314 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →